True North gives Indian drugmaker Biocon Biologics $3bn valuation through stake buy

Private equity investor True North has agreed an INR5.3bn ($74.6m) investment in Indian biosimilars drugmaker Biocon Biologics India to give the business a roughly $3bn valuation.